For: | Shailubhai K, Palejwala V, Arjunan KP, Saykhedkar S, Nefsky B, Foss JA, Comiskey S, Jacob GS, Plevy SE. Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis. World J Gastrointest Pharmacol Ther 2015; 6(4): 213-222 [PMID: 26558155 DOI: 10.4292/wjgpt.v6.i4.213] |
---|---|
URL: | https://www.wjgnet.com/2150-5349/full/v6/i4/213.htm |
Number | Citing Articles |
1 |
Fermented Rice Bran Supplementation Prevents the Development of Intestinal Fibrosis Due to DSS-Induced Inflammation in Mice. Nutrients 2021; 13(6): 1869 doi: 10.3390/nu13061869
|
2 |
Florence M. Brunel, Fa Liu, John P. Mayer. Successful Drug Discovery. 2019; : 1 doi: 10.1002/9783527814695.ch1
|
3 |
Mi-Rae Shin, Kyeong Jo Kim, Soo Hyun Kim, Su Ji Kim, Bu-Il Seo, Hyo-Jin An, Seong-Soo Roh. Comparative Evaluation between Sulfasalazine Alone and in Combination with Herbal Medicine on DSS-Induced Ulcerative Colitis Mice. BioMed Research International 2017; 2017: 1 doi: 10.1155/2017/6742652
|
4 |
N.S. Yarla, H. Gali, G. Pathuri, S. Smriti, M. Farooqui, J. Panneerselvam, G. Kumar, V. Madka, C.V. Rao. Targeting the paracrine hormone-dependent guanylate cyclase/cGMP/phosphodiesterases signaling pathway for colorectal cancer prevention. Seminars in Cancer Biology 2019; 56: 168 doi: 10.1016/j.semcancer.2018.08.011
|
5 |
Chelsea E. Hunter, Brian D. Hosfield, Fikir M. Mesfin, Anthony R. Pecoraro, Jianyun Liu, W. Christopher Shelley, Krishna Manohar, Troy A. Markel. Sildenafil attenuates intestinal injury in necrotizing enterocolitis independently of endothelial nitric oxide synthase. Journal of Pediatric Surgery 2022; 57(12): 967 doi: 10.1016/j.jpedsurg.2022.06.001
|
6 |
Andrea Brancale, Kunwar Shailubhai, Salvatore Ferla, Antonio Ricci, Marcella Bassetto, Gary S Jacob. Therapeutically targeting guanylate cyclase-C: computational modeling of plecanatide, a uroguanylin analog. Pharmacology Research & Perspectives 2017; 5(2): e00295 doi: 10.1002/prp2.295
|
7 |
Zahra Ghafouri, Saeid Seyyedian, Jafar Nikbakht, Ebrahim Kouhsari, Sara Bayat, Hamidreza Zargar, Gholamreza Houshmand. Effect of Sodium Cromoglycate on Acetic Acid-induced Ulcerative Colitis in Mice. The Korean Journal of Gastroenterology 2020; 75(1): 39 doi: 10.4166/kjg.2020.75.1.39
|
8 |
Thomas Kremsmayr, Aws Aljnabi, Juan B. Blanco-Canosa, Hue N. T. Tran, Nayara Braga Emidio, Markus Muttenthaler. On the Utility of Chemical Strategies to Improve Peptide Gut Stability. Journal of Medicinal Chemistry 2022; 65(8): 6191 doi: 10.1021/acs.jmedchem.2c00094
|
9 |
Haisheng Peng, Jiahe Wang, Jiayu Chen, Yanbo Peng, Xiaoxian Wang, Ying Chen, David L. Kaplan, Qun Wang. Challenges and opportunities in delivering oral peptides and proteins. Expert Opinion on Drug Delivery 2023; 20(10): 1349 doi: 10.1080/17425247.2023.2237408
|
10 |
Vipul Yadav, Felipe Varum, Roberto Bravo, Esther Furrer, Daniela Bojic, Abdul W. Basit. Inflammatory bowel disease: exploring gut pathophysiology for novel therapeutic targets. Translational Research 2016; 176: 38 doi: 10.1016/j.trsl.2016.04.009
|
11 |
Nian Liu, Kanuj Mishra, Andre C. Stiel, Vipul Gujrati, Vasilis Ntziachristos. The sound of drug delivery: Optoacoustic imaging in pharmacology. Advanced Drug Delivery Reviews 2022; 189: 114506 doi: 10.1016/j.addr.2022.114506
|
12 |
Chengfeng Xing, Tao Zhang, Xiaolin Liu, Canmei Li, Gang Yang, Hairong Zhang, Rui Wang, Kunhua Wang, Yinglei Miao, Danfeng Lan. Guanylin ligand protects the intestinal immune barrier by activating the guanylate cyclase-C signaling pathway. Acta Histochemica 2022; 124(1): 151811 doi: 10.1016/j.acthis.2021.151811
|
13 |
C Folgueira, S Barja-Fernandez, P Gonzalez-Saenz, V Pena-Leon, C Castelao, M Ruiz-Piñon, F F Casanueva, R Nogueiras, L M Seoane. Uroguanylin: a new actor in the energy balance movie. Journal of Molecular Endocrinology 2018; 60(2): R31 doi: 10.1530/JME-17-0263
|
14 |
Danial E. Baker. Formulary Drug Reviews: Plecanatide. Hospital Pharmacy 2017; 52(6): 400 doi: 10.1177/0018578717717623
|
15 |
Joshua R. Barton, Annie K. Londregran, Tyler D. Alexander, Ariana A. Entezari, Shely Bar-Ad, Lan Cheng, Angelo C. Lepore, Adam E. Snook, Manuel Covarrubias, Scott A. Waldman. Intestinal neuropod cell GUCY2C regulates visceral pain. Journal of Clinical Investigation 2023; 133(4) doi: 10.1172/JCI165578
|
16 |
Philip B Miner, William D Koltun, Gregory J Wiener, Marianela De La Portilla, Blas Prieto, Kunwar Shailubhai, Mary Beth Layton, Laura Barrow, Leslie Magnus, Patrick H Griffin. A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation. American Journal of Gastroenterology 2017; 112(4): 613 doi: 10.1038/ajg.2016.611
|
17 |
Huiya Zhang, Shiyu Chen. Cyclic peptide drugs approved in the last two decades (2001–2021). RSC Chemical Biology 2022; 3(1): 18 doi: 10.1039/D1CB00154J
|
18 |
Mengge Liu, Shiyu Li, Qian Zhang, Zhenrui Xu, Jiajia Wang, Hanxiao Sun. Oral engineered Bifidobacterium longum expressing rhMnSOD to suppress experimental colitis. International Immunopharmacology 2018; 57: 25 doi: 10.1016/j.intimp.2018.02.004
|
19 |
Michael DeMicco, Laura Barrow, Bernadette Hickey, Kunwar Shailubhai, Patrick Griffin. Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation. Therapeutic Advances in Gastroenterology 2017; 10(11): 837 doi: 10.1177/1756283X17734697
|
20 |
Annie Londregan, Tyler D. Alexander, Manuel Covarrubias, Scott A. Waldman. Fundamental Neurochemistry Review: The role of enteroendocrine cells in visceral pain. Journal of Neurochemistry 2023; 167(6): 719 doi: 10.1111/jnc.16022
|
21 |
Zaina T. Al-Salama, Yahiya Y. Syed. Plecanatide: First Global Approval. Drugs 2017; 77(5): 593 doi: 10.1007/s40265-017-0718-0
|
22 |
Baharak Moshiree, Philip Schoenfeld, Howard Franklin, Ali Rezaie. The Effect of Acid Suppression Therapy on the Safety and Efficacy of Plecanatide: Analysis of Randomized Phase III Trials. Clinical Therapeutics 2022; 44(1): 98 doi: 10.1016/j.clinthera.2021.11.009
|
23 |
Saumitra Sengupta, Srihari Pabbaraja, Goverdhan Mehta. Natural products from the human microbiome: an emergent frontier in organic synthesis and drug discovery. Organic & Biomolecular Chemistry 2024; 22(20): 4006 doi: 10.1039/D4OB00236A
|
24 |
Qinan Yin, Xingyue Zheng, Yujie Song, Liuyun Wu, Lian Li, Rongsheng Tong, Lizhu Han, Yuan Bian. Decoding signaling mechanisms: unraveling the targets of guanylate cyclase agonists in cardiovascular and digestive diseases. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1272073
|
25 |
Paula Mosińska, Maciej Salaga, Jakub Fichna. Novel investigational drugs for constipation-predominant irritable bowel syndrome: a review. Expert Opinion on Investigational Drugs 2016; 25(3): 275 doi: 10.1517/13543784.2016.1142532
|
26 |
Stuart M. Brierley, Luke Grundy, Joel Castro, Andrea M. Harrington, Gerhard Hannig, Michael Camilleri. Guanylate cyclase-C agonists as peripherally acting treatments of chronic visceral pain. Trends in Pharmacological Sciences 2022; 43(2): 110 doi: 10.1016/j.tips.2021.11.002
|
27 |
Hari Prasad, John Kandam Kulathu Mathew, Sandhya S. Visweswariah. Receptor Guanylyl Cyclase C and Cyclic GMP in Health and Disease: Perspectives and Therapeutic Opportunities. Frontiers in Endocrinology 2022; 13 doi: 10.3389/fendo.2022.911459
|
28 |
Nicole Martinez de Andino. Current treatment paradigm and landscape for the management of chronic idiopathic constipation in adults: Focus on plecanatide. Journal of the American Association of Nurse Practitioners 2018; 30(7): 412 doi: 10.1097/JXX.0000000000000090
|
29 |
Wen-Chi L Chang, Shet Masih, Anusha Thadi, Viren Patwa, Apoorva Joshi, Harry S Cooper, Vaseem A Palejwala, Margie L Clapper, Kunwar Shailubhai. Plecanatide-mediated activation of guanylate cyclase-C suppresses inflammation-induced colorectal carcinogenesis in Apc<sup>+/Min-FCCC</sup> mice. World Journal of Gastrointestinal Pharmacology and Therapeutics 2017; 8(1): 47-59 doi: 10.4292/wjgpt.v8.i1.47
|
30 |
Scott A Waldman, Michael Camilleri. Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders. Gut 2018; 67(8): 1543 doi: 10.1136/gutjnl-2018-316029
|
31 |
Illona-Marie Boulete, Anusha Thadi, Catherine Beaufrand, Viren Patwa, Apoorva Joshi, John A Foss, E Priya Eddy, Helene Eutamene, Vaseem A Palejwala, Vassilia Theodorou, Kunwar Shailubhai. Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity via activation of guanylate cyclase-C in rat models. World Journal of Gastroenterology 2018; 24(17): 1888-1900 doi: 10.3748/wjg.v24.i17.1888
|
32 |
T.A.S. Aguirre, D. Teijeiro-Osorio, M. Rosa, I.S. Coulter, M.J. Alonso, D.J. Brayden. Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials. Advanced Drug Delivery Reviews 2016; 106: 223 doi: 10.1016/j.addr.2016.02.004
|
33 |
Michael Camilleri. What’s in the pipeline for lower functional gastrointestinal disorders in the next 5 years?. American Journal of Physiology-Gastrointestinal and Liver Physiology 2019; 317(5): G640 doi: 10.1152/ajpgi.00205.2019
|
34 |
Crystal L. Kraft, Jeffrey A. Rappaport, Adam E. Snook, Amanda M. Pattison, John P. Lynch, Scott A. Waldman. GUCY2C maintains intestinal LGR5+ stem cells by opposing ER stress. Oncotarget 2017; 8(61): 102923 doi: 10.18632/oncotarget.22084
|
35 |
Ariana A. Entezari, Adam E. Snook, Scott A. Waldman. Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential. Expert Opinion on Therapeutic Targets 2021; 25(5): 335 doi: 10.1080/14728222.2021.1937124
|
36 |
Hannah A. Blair. Plecanatide in chronic idiopathic constipation and irritable bowel syndrome with constipation: a profile of its use in the USA. Drugs & Therapy Perspectives 2018; 34(12): 554 doi: 10.1007/s40267-018-0579-y
|
37 |
David S. Weinberg, Nathan R. Foster, Gary Della’Zanna, Ryan P. McMurray, Walter K. Kraft, Angela Pallotto, David M. Kastenberg, Leo C. Katz, Christopher H. Henry, Stephanie M. Moleski, Paul J. Limburg, Scott A. Waldman. Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers. Cancer Biology & Therapy 2021; 22(10-12): 544 doi: 10.1080/15384047.2021.1967036
|
38 |
Allison A. Aka, Jeff A. Rappaport, Amanda M. Pattison, Takami Sato, Adam E. Snook, Scott A. Waldman. Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer. Expert Review of Clinical Pharmacology 2017; 10(5): 549 doi: 10.1080/17512433.2017.1292124
|
39 |
Adi Caspi, Ariana A Entezari, Madison Crutcher, Adam E Snook, Scott A Waldman. Guanylyl Cyclase C as a Diagnostic and Therapeutic Target in Colorectal Cancer. Personalized Medicine 2022; 19(5): 457 doi: 10.2217/pme-2022-0026
|
40 |
Haidi Li, Jie Chao, Zixin Zhang, Guang Tian, Jun Li, Ninghui Chang, Chuanguang Qin. Liquid-Phase Total Synthesis of Plecanatide Aided by Diphenylphosphinyloxyl Diphenyl Ketone (DDK) Derivatives. Organic Letters 2020; 22(9): 3323 doi: 10.1021/acs.orglett.0c00616
|
41 |
Luísa Leite Barros, Alberto Queiroz Farias, Ali Rezaie. Gastrointestinal motility and absorptive disorders in patients with inflammatory bowel diseases: Prevalence, diagnosis and treatment. World Journal of Gastroenterology 2019; 25(31): 4414-4426 doi: 10.3748/wjg.v25.i31.4414
|
42 |
Walter Cabri, Paolo Cantelmi, Dario Corbisiero, Tommaso Fantoni, Lucia Ferrazzano, Giulia Martelli, Alexia Mattellone, Alessandra Tolomelli. Therapeutic Peptides Targeting PPI in Clinical Development: Overview, Mechanism of Action and Perspectives. Frontiers in Molecular Biosciences 2021; 8 doi: 10.3389/fmolb.2021.697586
|
43 |
Bianca N. Islam, Sarah K. Sharman, Yali Hou, Allison E. Bridges, Nagendra Singh, Sangmi Kim, Ravindra Kolhe, Jimena Trillo-Tinoco, Paulo C. Rodriguez, Franklin G. Berger, Subbaramiah Sridhar, Darren D. Browning. Sildenafil Suppresses Inflammation-Driven Colorectal Cancer in Mice. Cancer Prevention Research 2017; 10(7): 377 doi: 10.1158/1940-6207.CAPR-17-0015
|
44 |
Amanda N. Lisby, John C. Flickinger, Babar Bashir, Megan Weindorfer, Sanjna Shelukar, Madison Crutcher, Adam E. Snook, Scott A. Waldman. GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer. Expert Review of Precision Medicine and Drug Development 2021; 6(2): 117 doi: 10.1080/23808993.2021.1876518
|
45 |
Satish S.C. Rao. Plecanatide: a new guanylate cyclase agonist for the treatment of chronic idiopathic constipation. Therapeutic Advances in Gastroenterology 2018; 11 doi: 10.1177/1756284818777945
|
46 |
Amanda M. Pattison, Erik S. Blomain, Dante J. Merlino, Fang Wang, Mary Ann S. Crissey, Crystal L. Kraft, Jeff A. Rappaport, Adam E. Snook, John P. Lynch, Scott A. Waldman, S. R. Blanke. Intestinal Enteroids Model Guanylate Cyclase C-Dependent Secretion Induced by Heat-Stable Enterotoxins. Infection and Immunity 2016; 84(10): 3083 doi: 10.1128/IAI.00639-16
|
47 |
Charles F. Barish, Robert A. Crozier, Patrick H. Griffin. Long-term treatment with plecanatide was safe and tolerable in patients with irritable bowel syndrome with constipation. Current Medical Research and Opinion 2019; 35(1): 81 doi: 10.1080/03007995.2018.1527303
|
48 |
Peng Li, Evan Wuthrick, Jeff A. Rappaport, Crystal Kraft, Jieru E. Lin, Glen Marszalowicz, Adam E. Snook, Tingting Zhan, Terry M. Hyslop, Scott A. Waldman. GUCY2C Signaling Opposes the Acute Radiation-Induced GI Syndrome. Cancer Research 2017; 77(18): 5095 doi: 10.1158/0008-5472.CAN-17-0859
|
49 |
Darren M. Brenner, Ronald Fogel, Spencer D. Dorn, Richard Krause, Paul Eng, Robert Kirshoff, Anhthu Nguyen, Robert A. Crozier, Leslie Magnus, Patrick H. Griffin. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials. American Journal of Gastroenterology 2018; 113(5): 735 doi: 10.1038/s41395-018-0026-7
|
50 |
Soheil Haddadzadegan, Farid Dorkoosh, Andreas Bernkop-Schnürch. Oral delivery of therapeutic peptides and proteins: Technology landscape of lipid-based nanocarriers. Advanced Drug Delivery Reviews 2022; 182: 114097 doi: 10.1016/j.addr.2021.114097
|
51 |
Katia Cappelli, Rodolfo Gialletti, Beniamino Tesei, Gabrio Bassotti, Katia Fettucciari, Stefano Capomaccio, Laura Bonfili, Massimiliano Cuccioloni, Anna Maria Eleuteri, Andrea Spaterna, Fulvio Laus. Guanylin, Uroguanylin and Guanylate Cyclase-C Are Expressed in the Gastrointestinal Tract of Horses. Frontiers in Physiology 2019; 10 doi: 10.3389/fphys.2019.01237
|
52 |
Állan S. Pires, William F. Porto, Pryscilla O. Castro, Octavio L. Franco, Sérgio A. Alencar. Theoretical structural characterization of lymphoguanylin: A potential candidate for the development of drugs to treat gastrointestinal disorders. Journal of Theoretical Biology 2017; 419: 193 doi: 10.1016/j.jtbi.2017.02.016
|
53 |
Rodger A. Liddle. Guanylyl cyclase C ameliorates visceral pain: an unsuspected link. Journal of Clinical Investigation 2023; 133(4) doi: 10.1172/JCI166703
|
54 |
Hiroyuki Takita, Adam S. Darwich, Amais Ahmad, Amin Rostami‐Hodjegan. Application of the Nested Enzyme‐Within‐Enterocyte (NEWE) Turnover Model for Predicting the Time Course of Pharmacodynamic Effects. CPT: Pharmacometrics & Systems Pharmacology 2020; 9(11): 617 doi: 10.1002/psp4.12557
|
55 |
Haihua Zhang, Wuying Lang, Xin Liu, Jiangsong Bai, Qinghui Jia, Qiumei Shi. Procyanidin A1 alleviates DSS-induced ulcerative colitis via regulating AMPK/mTOR/p70S6K-mediated autophagy. Journal of Physiology and Biochemistry 2022; 78(1): 213 doi: 10.1007/s13105-021-00854-5
|
56 |
Martina Rekatsina, Giustino Varrassi. Emerging potential therapies for chronic abdominal visceral pain: an overview. Advancements in Health Research 2024; 1(1) doi: 10.4081/ahr.2024.2
|
57 |
Arkadiusz Michalak, Paula Mosińska, Jakub Fichna. Polyunsaturated Fatty Acids and Their Derivatives: Therapeutic Value for Inflammatory, Functional Gastrointestinal Disorders, and Colorectal Cancer. Frontiers in Pharmacology 2016; 7 doi: 10.3389/fphar.2016.00459
|
58 |
Jeffrey A. Rappaport, Scott A. Waldman. The Guanylate Cyclase C—cGMP Signaling Axis Opposes Intestinal Epithelial Injury and Neoplasia. Frontiers in Oncology 2018; 8 doi: 10.3389/fonc.2018.00299
|